

Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal)

Technology appraisal guidance

Published: 23 January 2013

www.nice.org.uk/guidance/ta273

Contents

| | |
|-----------------------------|---|
| Advice..... | 3 |
| Background | 4 |
| Information | 5 |
| Related NICE guidance | 5 |

Advice

NICE is unable to recommend the use in the NHS of tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia because no evidence submission was received from the manufacturer of the technology.

Background

The manufacturer of tadalafil (Lilly) was invited to submit evidence for this single technology appraisal in August 2012.

In September 2012, the manufacturer informed NICE that it would not be making an evidence submission for the appraisal of tadalafil for the treatment of benign prostatic hyperplasia. The manufacturer stated that there is insufficient evidence available to be able to undertake the appropriate analysis required to estimate the cost effectiveness of tadalafil within the defined treatment pathway outlined in [Lower urinary tract symptoms: the management of lower urinary tract symptoms in men](#) (NICE clinical guideline 97).

NICE has therefore terminated this single technology appraisal.

Information

NHS organisations should take into account the reasons why the manufacturer did not make an evidence submission when considering whether or not to recommend local use of tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia. If, after doing this, organisations still wish to consider tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia, they should follow the advice set out in [Good practice guidance on managing the introduction of new healthcare interventions and links to NICE technology appraisal guidance](#) which outlines the approach that should be adopted in circumstances where NICE guidance is unavailable.

NICE will review the position at any point if the manufacturer indicates that it wishes to make a full submission.

Related NICE guidance

For information about NICE guidance that has been issued or is in development, see the [NICE website](#).

- [Lower urinary tract symptoms: the management of lower urinary tract symptoms in men](#). NICE clinical guideline 97 (2010).
- [Referral guidelines for suspected cancer in adults and children](#). NICE clinical guideline 27 (2005).
- [Laparoscopic prostatectomy for benign prostatic obstruction](#). NICE interventional procedure guidance 275 (2008).